Evaluation of cognitive function in healthy older subjects treated with fesoterodine

Postgraduate Medicine

Volumn 124, Issue 3, 2012, Pages 7-15

  Kay, Gary G ^a   Maruff, Paul ^b,c   Scholfield, David ^a   Malhotra, Bimal ^d   Whelan, Laurence ^e   Darekar, Amanda ^d   Martire, Diane L ^e  

^a Drug Development   (United States)

^b Scientific Division   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e PFIZER INC   (United States)

Author keywords

Antimuscarinic; Cognition; Elderly; Fesoterodine; Memory

Indexed keywords

ALPRAZOLAM; FESOTERODINE; PLACEBO; BENZHYDRYL DERIVATIVE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

AGED; ARTICLE; ATAXIA; COGNITION; COMPUTER ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LEARNING; MALE; MINI MENTAL STATE EXAMINATION; NORMAL HUMAN; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REY AUDITORY VERBAL LEARNING TEST; SEDATION; SIDE EFFECT; SOMNOLENCE; TASK PERFORMANCE; VOLUNTEER; XEROSTOMIA; ANALYSIS OF VARIANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; NEUROPSYCHOLOGICAL TEST; REGRESSION ANALYSIS;

AGED; AGED, 80 AND OVER; ALPRAZOLAM; ANALYSIS OF VARIANCE; BENZHYDRYL COMPOUNDS; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GABA MODULATORS; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MUSCARINIC ANTAGONISTS; NEUROPSYCHOLOGICAL TESTS; PLACEBOS;

EID: 84867892054     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.05.2543     Document Type: Article

References (46)

1. Abrams P, Cardozo L, Fall M, et al; Standardisation Sub-commmittee of the International Contience Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178.
2. Haylen BT, de Ridder D, Freeman RM, et al; International Urogyneco-logical Association; International Contenence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4-20.
3. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6): 1306-1315.
4. Nuotio M, Tammela TL, Luukkaala T, Jylha M. Urgency and urge incontinence in an older population: ten-year changes and their association with mortality. Aging Clin Exp Res. 2002;14(5):412-419.
5. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6(11 suppl): 574-579.
6. Andersson KE. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol. 2004;3(1):46-53.
7. Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5- hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):481-489.
8. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148(5): 565-578.
9. Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract. 2010;64(9):1279-1286.
10. Kay GG, Abou-Donia MB, Messer WS Jr, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195-2201.
11. Wagg AS, Cardozo L, Chapple C, et al. Overactive bladder syndrome in older people. BJU Int. 2007;99(3):502-509.
12. DuBeau CE, Kuchel GA, Johnson T 2nd, Palmer MH, Wagg A; Fourth International consultation on Incontenence. Incontinence in the frail elderly: report from the 4th International Consultation on Incontinence. Neurourol Urodyn. 2010;29(1):165-178.
13. Han L, Agostini J V, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc. 2008;56(12):2203-2210.
14. Nebes RD, Pollock BG, Halligan EM, Kirshner MA, Houck PR. Serum anticholinergic activity and motor performance in elderly persons. J Gerontol A Biol Sci Med Sci. 2007;62(1):83-85.
15. Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf. 2011;10(5):751-765.
16. Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62 (suppl 21):11-14.
17. Sink KM, Thomas J 3rd, Xu H, Craig B, Kritchevsky S, Sands LP Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008; 56(5):847-853.
18. Jewart RD, Green J, Lu CJ, Cellar J, Tune LE. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry. 2005;13(4): 324-328.
19. Nikaido AM, Ellinwood EH Jr, Heatherly DG, Gupta SK. Age-related increase in CNS sensitivity to benzodiazepines as assessed by task difficulty. Psychopharmacology (Berl). 1990;100(1):90-97.
20. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204-1212.
21. Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int. 2008;102(1):56-61.
22. Dmochowski RR, Peters KM, Morrow JD, et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology. 2010;75(1):62-68.
23. Kraus SR, Ruiz-Cerdá JL, Martire D, Wang JT, Wagg AS. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology. 2010;76(6):1350-1357.
24. Wagg A, Khullar V, Marschall-Kehrel D, et al. Assessment of fesoterodine treatment in older people with overactive bladder: Results of SOFIA, a double-blind, placebo-controlled, pan-European trial. European Urology Supplements. 2011;10:276-277.
25. Callegari E, Malhotra B, Bungay PJ, et al. A comprehensive nonclinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011;72(2):235-246.
26. Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl). 2005;183(2):133-143.
27. Leufkens TR Vermeeren A, Smink BE, van Ruitenbeek P, Ramaekers JG Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. Psychopharmacology (Berl). 2007;191(4):951-959.
28. Vermeeren A, Jackson JL, Muntjewerff ND, et al. Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests. Psychopharmacology (Berl). 1995;118(1):1-9.
29. Malhotra B, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008;46(11):556-563.
30. Malhotra B, Sachse R, Wood N. Influence of food on the pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2009;47(6): 384-390.
31. Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology (Berl). 1984;84(4):452-456.
32. Maruff P, Thomas E, Cysique L, et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol. 2009;24(2): 165-178.
33. Callahan CD, Johnstone B. The clinical utility of the Rey Auditory-Verbal Learning Test in medical rehabilitation. J Clin Psychol Med Settings. 1994;1:261-268.
34. Falleti MG, Maruff P, Collie A, Darby DG. Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. J Clin Exp Neuropsychol. 2006;28(7):1095-1112.
35. Falleti MG, Maruff P, Collie A, Darby DG, McStephen M. Qualitative similarities in cognitive impairment associated with 24 h of sustained wakefulness and a blood alcohol concentration of 0.05%. J Sleep Res. 2003;12(4):265-274.
36. Fredrickson A, Snyder PJ, Cromer J, Thomas E, Lewis M, Maruff P. The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine. Hum Psychopharmacol. 2008;23(5):425-436.
37. Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther. 2005;27(1):127-138.
38. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharma-cother. 2008;9(10):1787-1796.
39. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50(2):317-326.
40. Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc. 1998;46(1):8-13.
41. Kay G, Kardiasmenos K, Crook T Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutyinin chloride ER on recent memory in older subjects Presented at: International Continence Society; November 26 to December 1, 2006; Christchurch, New Zealand.
42. Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int. 2005;96(7):1055-1062.
43. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008;62(11):1792-1800.
44. Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf. 2009;8(6):615-626.
45. Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64(9):1294-1300.
46. US Census Bureau. U.S. Summary: 2000, Census 2000 Profile. U.S. Department of Commerce. Available at: http://www.census.gov/ prod/2002pubs/c2kprof00-us.pdf. Accessed June 9, 2008.